Antimicrobial Resistance Surveillance Market Report- Trend Analysis, Industry Share, Emerging Demands, Top Major Players, Current Growth, and Forecast to 2028

The global antimicrobial resistance surveillance market in terms of revenue was estimated to be worth $5.9 billion in 2023 and is poised to reach $7.7 billion by 2028, growing at a CAGR of 5.6% from 2023 to 2028.

Logo

Northbrook, IL 60062 -- (SBWire) -- 11/21/2023 --Antimicrobial Resistance Surveillance Market by Solution (Kits, System, Surveillance Software, Service), Application (Clinical Diagnostics, Public Health Surveillance), End User (Hospitals, Clinics, Academic, Research Institutes) - Global Forecast to 2028", is projected to reach USD 7.7 billion by 2028 from USD 5.9 billion in 2023, at a CAGR of 5.6% during the forecast period. Growth in this market is majorly driven by growing prevalence of infections caused by drug-resistance pathogens, innovations in diagnostic technologies, and growing government initiatives to combat antimicrobial-resistance species.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=21323165

Browse in-depth TOC on "Antimicrobial Resistance Surveillance Market"
158 - Tables
58 - Figures
234 – Pages

Key Market Players:

The prominent players in this market are Biomerieux (France), Lumed (US), Liofilchem S.r.l. (Italy), BioSpace (US), Bruker (US), Bio-Rad (US), Abbott Laboratories (US), Qiagen (Germany), Cepheid (US), Accelerate Diagnostics, Inc. (US), Roche Diagnostics (Switzerland), Luminex Corporation (US), Merck KgaA (Germany), Thermo Fisher Scientific (US), Danaher (US), Becton, Dickinson and Company (US), OpGen, Inc. (US), Alifax S.r.l. (Italy), Wolters Kluwer N.V. (US), and Bioanalyse (Turkey).

Driver: Growing prevalence of infections caused by drug-resistance pathogens

According to a published article by NCBI, within India, the incidence of VRE infections is on the rise, fluctuating between 1% and 8.7%. Our own investigation further demonstrates an escalating VRE infection rate in the bloodstream, climbing from 6.12% in 2018 to 19.2% in 2020. The growing number of epidemic outbreaks caused by drug-resistance pathogens, such as methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE), multi-drug-resistant Mycobacterium tuberculosis (MDR-TB), and carbapenem-resistant Enterobacteriaceae (CRE) gut bacteria is also propelling the demand for antimicrobial resistance surveillance solutions.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=21323165

The diagnostic kits segment is expected to account for the largest share of the market during the forecast period

On the basis of solutions, the global antimicrobial resistance surveillance market has been segmented into diagnostic kits, diagnostic systems, surveillance software, and services. In 2023, the diagnostic kits segment is estimated to command the largest share of the global antimicrobial resistance surveillance market. The large share of this segment can primarily be attributed to the increasing demand for rapid and accurate diagnostics for antimicrobial resistance. Diagnostic kits are used to detect the presence of antimicrobial-resistant bacteria in clinical samples, such as blood, urine, and respiratory secretions.

The clinical diagnostics segment is expected to account for the largest share of the market during the forecast period.

On the basis of application, the global antimicrobial resistance surveillance market has been segmented into clinical diagnostics, public health surveillance, and other applications. In 2023, the clinical diagnostics segment is expected to command the largest share of the global antimicrobial resistance surveillance market. The growth in this segment can be attributed to factors such as need to improve patient outcomes, increasing prevalence of antimicrobial resistance, used to determine the susceptibility of bacteria to different antimicrobial agents.

The hospitals & clinics segment is expected to account for the largest share of the market
On the basis of end users, the global antimicrobial resistance surveillance market has been segmented into hospitals & clinics, research and academic institutes, and others. In 2023, the hospitals & clinics segment is expected to command the largest share of the global antimicrobial resistance surveillance market.The large share of this segment can be attributed to the fact that because they are the primary settings where antimicrobial-resistant infections occur and they are required to conduct antimicrobial resistance surveillance.

Asia Pacific to witness the highest growth during the forecast period.

In 2022, North America accounted for the largest share the antimicrobial resistance surveillance market. During forecast period, Asia Pacific to witness high growth rate. America. The Asia Pacific region is expected to offer significant opportunities for the growth of the antimicrobial susceptibility testing market. This is because of the region's large population and its mix of growing and developed economies, such as Japan, China, and India. In addition, markets in developed countries are becoming increasingly saturated. As a result, manufacturers and suppliers are shifting their focus to Asia Pacific.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=21323165

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America's best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com

Media Relations Contact

Aashish Mehra
18886006441
https://www.marketsandmarkets.com/Market-Reports/antimicrobial-resistance-surveillance-market-21323165.html

View this press release online at: http://rwire.com/1380293